Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29764078 | 0.81 | KMT2A (0.65) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1463333 | 0.81 | KMT2A (0.65) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1428216 | 0.79 | KDM4E (1.00) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL28019873 | 0.79 | KDM4E (0.64) | KDM4EALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL22021637 | 0.79 | KDM4E (0.64) | KDM4EALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL1521056 | 0.79 | KDM4E (0.64) | KDM4EALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL30883267 | 0.79 | KDM4E (1.00) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL27639917 | 0.79 | KDM4E (0.64) | KDM4EALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL22021642 | 0.79 | KDM4E (0.64) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL8986856 | 0.79 | KDM4E (1.00) | KDM4EALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509460-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-3957633-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2022-02-23 | — | — | EP | disclosed |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2022-01-25 | — | — | US | disclosed |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2020-11-12 | — | — | US | disclosed |
| WO-2020211822-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | 成都海创药业有限公司 | 2020-10-22 | — | — | WO | disclosed |
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-07 | — | — | US | disclosed |
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
| EP-1558260-A4 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | NPS PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| CN-1708306-A | Quinazolinone compounds as calcilytics | NPS PHARMA INC (US) | 2005-12-14 | — | — | CN | disclosed |
| EP-1558260-A2 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004041755-A2 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| US-4183931-A | SEDATIVE-HYPNOTICS, ANTICONVULSANTS, CENTRAL NERVOUS SYSTEM DEPRESSANTS | RESEARCH CORPORATION (US) | 1980-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | KDM4E 2967/4885ALDH1A1 2255/4885MAPT 1672/4885 |
| US-20070275956-A1 | Novel Heterocyclic Compounds | CYP46A1, DHCR7, NPC1L1 | KDM4E 4107/4885ALDH1A1 1358/4885MAPT 162/4885 |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | KDM4E 2530/4885ALDH1A1 4181/4885MAPT 2405/4885 |
| US-12509460-B2 | Methods and compositions for modulating splicing | SF3B1, RTCB, RBM17 | KDM4E 2036/4885ALDH1A1 3032/4885MAPT 4636/4885 |
| US-10702521-B2 | Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones | DHPS, HSD17B11, GNE | KDM4E 2813/4885ALDH1A1 300/4885MAPT 2757/4885 |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | KDM4E 4404/4885ALDH1A1 548/4885MAPT 3436/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | KDM4E 2385/4885ALDH1A1 2811/4885MAPT 1883/4885 |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | KDM4E 4404/4885ALDH1A1 548/4885MAPT 3436/4885 |
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | CALCR, CALCRL, CASR | KDM4E 4608/4885ALDH1A1 4096/4885MAPT 4420/4885 |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GMPS, GNE, DHPS | KDM4E 1647/4885ALDH1A1 1200/4885MAPT 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.